A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of
TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX)
as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal
junction (GEJ) adenocarcinoma.